M&As this week: Northern Biologics, Novartis, Asahi Glass
Northern Biologics has merged with Mosaic Biomedicals with the aim of expanding its pipeline and accelerating the development of MSC-1.
Pursuant to the agreement, Northern Biologics will be responsible for funding the early clinical development of MSC-1 through the funds raised from a series A financing round led by Versant Ventures.
The agreement enables Northern Biologics to develop novel therapeutic antibodies.
Novartis plans to acquire Encore Vision in order to strengthen its product pipeline for highly prevalent and unmet medical needs.
Asahi Glass has announced that it will acquire CMC Biologics for a purchase consideration of $508.6m.
William Blair & Company is acting as the financial advisor, while Shearman & Sterling is acting as the legal advisor for the acquisition.
The acquisition will enable Asahi Glass to expand its presence in the biopharmaceutical contract services.
Sun Pharmaceutical Industries has acquired a 14.58% stake in scPharmaceuticals for a purchase consideration of $13m in cash.
As part of the transaction, Sun Pharma acquired 13 million series B preferred stock of the target company.
A 5% stake in Shanghai Shenqi Pharmaceutical Investment Management (formerly Shanghai Wingsung Investment Management), a pharmaceutical company, was sold by an investment company.
The investment company’s stake has come down to 1.21% from 6.21%, as a result of the sale.
Japanese pharmaceutical company Taisho Pharmaceutical has agreed to acquire Dr Program from Kyorin Pharmaceutical (formerly KYORIN). The transaction will be effective from 1 April.
MeTiS Biotechnologies, a contract research organisation based in France, has been acquired by French biotechnology company Indicia Production.
The acquirer company intends to extend its current traditional microbiological media offering through the acquisition.
Pharmaceutical company PixarBio Corporation has agreed to acquire a research and clinical-stage biomaterials and biotechnology company named InVivo Therapeutics Holdings.
The acquisition involves a purchase consideration of $77m in shares and will enable the acquirer company to develop the post-surgical pain treatment, NeuroRelease.
M Pharmaceutical intends to acquire US-based medical product development company, 40J’s LLC.
Based in Canada, M Pharmaceutical develops technologies for obesity and weight management.
The acquisition involves a purchase consideration of C$1.5m ($1.12m) in cash to be paid over two years, certain milestone-based payments, and issue of 80 million shares to the target company.